IRadimed
IRMD
84.98
-0.49
-0.57%
IRadimed
US · IRMD
#3190 by market cap
84.98
-0.49
-0.57%
Live - 5344 symbols - heartbeat 331s ago
· 2026-10-08 09:57
Pre-market
86.50
+1.21%
After-hours
85.47
0.00%
- Market cap
- 1.09B
- P/E (TTM)i
- 47.47
- P/Bi
- 10.68
- EPSi
- 1.75
- Div yieldi
- 0.87%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on IRMD?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 49.22, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +14.43% YoY
Margins
- Gross margin
- 76.75%
- Operating margin
- 31.20%
- Net margin
- 26.82%
Key ratios & quality
- PEG ratioi
- 2.31
- Altman Z-Scorei
- 49.22
PEG uses trailing P/E against the 3-year net income growth rate (20.56%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.44M | 38.52M | 31.72M | 41.81M | 53.30M | 65.56M | 73.24M | 83.81M |
| Gross profit | 23.23M | 29.70M | 23.57M | 32.05M | 41.28M | 50.16M | 56.35M | 64.32M |
| Selling & admin expenses | 15.71M | 19.62M | 22.43M | 20.33M | 23.38M | 27.26M | 31.55M | 35.20M |
| Research & development | 1.52M | 1.43M | 1.90M | 1.91M | 2.28M | 2.86M | 2.83M | 2.98M |
| Operating profit | 6.00M | 8.65M | -756.09K | 9.82M | 15.63M | 20.04M | 21.97M | 26.15M |
| Pretax profit | 6.20M | 9.04M | -616.88K | 9.84M | 16.18M | 21.74M | 24.28M | 28.36M |
| Tax | -106.14K | -587.64K | -1.99M | 510.82K | 3.35M | 4.55M | 5.04M | 5.88M |
| Net profit | 6.30M | 9.63M | 1.37M | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Basic EPS | 1 | 1 | 0 | 1 | 1 | 1 | 2 | 2 |
| Diluted EPS | 0.52 | 0.78 | 0.11 | 0.74 | 1.02 | 1.35 | 1.50 | 1.75 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 19.51M | 20.41M | 21.20M | 22.69M | 21.98M | 20.47M |
| Gross profit | 14.84M | 15.96M | 16.49M | 17.03M | 16.81M | 15.16M |
| Selling & admin expenses | 8.79M | 8.29M | 8.99M | 9.14M | 8.62M | 8.11M |
| Research & development | 624.00K | 877.00K | 674.36K | 799.03K | 956.00K | 657.00K |
| Operating profit | 5.43M | 6.79M | 6.83M | 7.09M | 7.24M | 6.39M |
| Pretax profit | 5.95M | 7.33M | 7.30M | 7.79M | 7.77M | 6.89M |
| Tax | 1.26M | 1.55M | 1.72M | 1.35M | 1.95M | 1.67M |
| Net profit | 4.69M | 5.77M | 5.58M | 6.44M | 5.82M | 5.22M |
| Basic EPS | 0 | 0 | 0 | 1 | 0 | 0 |
| Diluted EPS | 0.37 | 0.45 | 0.43 | 0.50 | 0.45 | 0.41 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 44.54M | 58.96M | 63.74M | 76.24M | 77.49M | 76.00M | 75.24M | 81.20M |
| Cash & ST investments | 34.38M | 46.25M | 51.98M | 62.50M | 57.96M | 49.76M | 52.23M | 51.16M |
| Inventory | 4.06M | 3.64M | 3.93M | 4.30M | 5.37M | 12.82M | 10.40M | 11.62M |
| Total assets | 48.44M | 66.73M | 71.07M | 82.88M | 85.51M | 92.16M | 98.33M | 108.78M |
| Total current liabilities | 4.69M | 5.86M | 4.92M | 6.82M | 8.55M | 16.33M | 8.51M | 10.18M |
| Short-term debt | -- | 240.84K | 255.70K | 276.57K | 293.47K | 427.96K | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 6,496,525.00 | 11,204,469.00 | 9,682,008.00 | 10,707,616.00 | 11,840,760.00 | 20,735,934.00 | 11,507,000.00 | 14,158,000.00 |
| Total equity | 41.95M | 55.52M | 61.38M | 72.17M | 73.67M | 71.42M | 86.82M | 94.62M |
| Retained earnings | 26.67M | 36.30M | 37.67M | 46.99M | 47.26M | 43.26M | 56.79M | 64.23M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 75.14M | 77.37M | 84.92M | 81.20M | 86.42M | 86.72M |
| Cash & ST investments | 50.33M | 53.00M | 56.53M | 51.16M | 56.37M | 59.08M |
| Inventory | 10.56M | 11.20M | 11.73M | 11.62M | 11.88M | 12.26M |
| Total assets | 101.73M | 106.45M | 114.72M | 108.78M | 114.39M | 114.98M |
| Total current liabilities | 8.47M | 8.81M | 12.80M | 10.18M | 12.12M | 9.16M |
| Short-term debt | 59.22K | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 11,675,005.00 | 12,146,103.00 | 16,369,808.00 | 14,158,000.00 | 15,875,000.00 | 13,227,000.00 |
| Total equity | 90.05M | 94.30M | 98.35M | 94.62M | 98.51M | 101.75M |
| Retained earnings | 59.32M | 62.93M | 66.34M | 64.23M | 67.49M | 70.15M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 7.38M | 10.23M | 5.82M | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M |
| Depreciation & amortization | 1.11M | 1.24M | 1.34M | 1.41M | 670.67K | 765.18K | 818.00K | 1.17M |
| Free cash flow | 7.11M | 9.75M | 5.18M | 10.52M | 8.17M | 5.46M | 16.81M | 16.53M |
| Dividends paid | -- | -- | -- | 0 | -12.56M | -13.22M | -13.68M | -15.04M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 28.03M | 43.48M | 50.07M | 62.00M | 57.96M | 49.76M | 52.23M | 51.16M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 4.29M | 7.75M | 6.99M | 5.92M | 8.29M | 5.94M |
| Depreciation & amortization | 194.00K | 208.00K | 383.32K | 380.68K | 455.00K | 410.00K |
| Free cash flow | 375.00K | 4.92M | 5.72M | 5.51M | 7.82M | 5.50M |
| Dividends paid | -2.16M | -2.16M | -2.16M | -8.55M | -2.56M | -2.56M |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 50.33M | 53.00M | 56.53M | 51.16M | 56.37M | 59.08M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 16.84 | 19.76 | 2.34 | 13.96 | 17.59 | 23.70 | 24.31 | 24.78 |
| ROA %i | 14.42 | 16.72 | 1.99 | 12.12 | 15.24 | 19.35 | 20.20 | 21.71 |
| ROIC %i | 16.37 | 18.08 | 2.08 | 13.39 | 16.43 | 21.05 | 21.81 | 23.02 |
| 5-year avg ROE %i | 17.02 | 17.85 | 12.62 | 10.89 | 14.10 | 15.47 | 16.38 | 20.87 |
| EBIT margin %i | 19.72 | 22.45 | -2.38 | 23.48 | 29.32 | 30.56 | 29.99 | 31.20 |
| FCF / sales %i | 23.36 | 25.31 | 16.33 | 25.15 | 15.32 | 8.32 | 22.95 | 19.72 |
| Current ratioi | 9.50 | 10.06 | 12.96 | 11.18 | 9.06 | 4.65 | 8.84 | 7.98 |
| Quick ratioi | 8.23 | 9.14 | 11.50 | 9.91 | 8.33 | 3.80 | 7.38 | 6.37 |
| Debt / assetsi | 0.00 | 4.43 | 3.82 | 2.99 | 2.58 | 2.22 | 0.00 | 0.00 |
| LT debt / equityi | -- | 4.89 | 4.01 | 3.06 | 2.60 | 2.26 | 0.00 | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -1.23 | 5.83 | 11.18 | 11.16 | 11.44 | 27.39 | 20.54 | 16.28 |
| Net income CAGR (3Y) %i | -5.75 | 10.11 | 39.92 | 13.95 | 10.03 | 132.44 | 27.29 | 20.56 |
| FCF CAGR (3Y) %i | -1.02 | 7.34 | 25.98 | 13.93 | -5.72 | 1.75 | 16.92 | 26.48 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 23.81 | 23.75 | 23.31 | 24.78 | 25.04 | 23.52 |
| ROA %i | 20.85 | 21.04 | 20.28 | 21.71 | 21.85 | 20.82 |
| ROIC %i | 23.53 | 23.75 | 23.31 | 23.02 | 25.04 | 23.52 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 30.14 | 30.67 | 30.87 | 31.20 | 32.40 | 31.92 |
| FCF / sales %i | 18.33 | 17.17 | 17.33 | 19.72 | 27.78 | 28.43 |
| Current ratioi | 8.87 | 8.78 | 6.64 | 7.98 | 7.13 | 9.46 |
| Quick ratioi | 7.44 | 7.25 | 5.50 | 6.37 | 5.76 | 7.89 |
| Debt / assetsi | 0.06 | 0.00 | 0.00 | 0.00 | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI)100.00%
Quote time 2026-10-08 09:57:30 · For reference only, not investment advice and not tailored to your situation.